The stock price of Vertex Pharmaceuticals has seen a decrease in the current session but has increased over the past month and year. The company's P/E ratio is lower than the industry average, which could suggest that the stock is undervalued or that shareholders do not expect the company to perform better in the future. However, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should not be used in isolation.